Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus

Byungji Kim; Hong Bo Pang; Jinyoung Kang; Ji Ho Park; Erkki Ruoslahti; Michael J. Sailor

doi:10.1038/s41467-018-04390-7

Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus

Byungji Kim, Hong Bo Pang, Jinyoung Kang, Ji Ho Park, Erkki Ruoslahti, Michael J. Sailor

Pharmaceutics

Research output: Contribution to journal › Article › peer-review

123 Scopus citations

Abstract

The incidence of adverse effects and pathogen resistance encountered with small molecule antibiotics is increasing. As such, there is mounting focus on immunogene therapy to augment the immune system's response to infection and accelerate healing. A major obstacle to in vivo gene delivery is that the primary uptake pathway, cellular endocytosis, results in extracellular excretion and lysosomal degradation of genetic material. Here we show a nanosystem that bypasses endocytosis and achieves potent gene knockdown efficacy. Porous silicon nanoparticles containing an outer sheath of homing peptides and fusogenic liposome selectively target macrophages and directly introduce an oligonucleotide payload into the cytosol. Highly effective knockdown of the proinflammatory macrophage marker IRF5 enhances the clearance capability of macrophages and improves survival in a mouse model of Staphyloccocus aureus pneumonia.

Original language	English (US)
Article number	1969
Journal	Nature communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-04390-7
State	Published - Dec 1 2018

Bibliographical note

Funding Information:
This work supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017, in part by grant CA152327 from the National Cancer Institute of the U.S. National Institutes of Health (E.R.), and by grant EB022652 from National Institute of Biomedical Imaging and Bioengineering (H.P.). The content of the information within this document does not necessarily reflect the position or the policy of the Government. Furthermore, this project has been funded in part by the National Institutes of Health, through contract number R01 AI132413-01

Funding Information:
This work supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017, in part by grant CA152327 from the National Cancer Institute of the U.S. National Institutes of Health (E.R.), and by grant EB022652 from National Institute of Biomedical Imaging and Bioengineering (H.P.). The content of the information within this document does not necessarily reflect the position or the policy of the Government. Furthermore, this project has been funded in part by the National Institutes of Health, through contract number R01 AI132413-01.

Publisher Copyright:
© 2018 The Author(s).

Publisher link

10.1038/s41467-018-04390-7

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958120

Find It

Find It at U of M Libraries

Cite this

@article{5104e334d4b9437dbaf4f1d9ab9d4876,

title = "Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus",

abstract = "The incidence of adverse effects and pathogen resistance encountered with small molecule antibiotics is increasing. As such, there is mounting focus on immunogene therapy to augment the immune system's response to infection and accelerate healing. A major obstacle to in vivo gene delivery is that the primary uptake pathway, cellular endocytosis, results in extracellular excretion and lysosomal degradation of genetic material. Here we show a nanosystem that bypasses endocytosis and achieves potent gene knockdown efficacy. Porous silicon nanoparticles containing an outer sheath of homing peptides and fusogenic liposome selectively target macrophages and directly introduce an oligonucleotide payload into the cytosol. Highly effective knockdown of the proinflammatory macrophage marker IRF5 enhances the clearance capability of macrophages and improves survival in a mouse model of Staphyloccocus aureus pneumonia.",

author = "Byungji Kim and Pang, {Hong Bo} and Jinyoung Kang and Park, {Ji Ho} and Erkki Ruoslahti and Sailor, {Michael J.}",

note = "Funding Information: This work supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017, in part by grant CA152327 from the National Cancer Institute of the U.S. National Institutes of Health (E.R.), and by grant EB022652 from National Institute of Biomedical Imaging and Bioengineering (H.P.). The content of the information within this document does not necessarily reflect the position or the policy of the Government. Furthermore, this project has been funded in part by the National Institutes of Health, through contract number R01 AI132413-01 Funding Information: This work supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017, in part by grant CA152327 from the National Cancer Institute of the U.S. National Institutes of Health (E.R.), and by grant EB022652 from National Institute of Biomedical Imaging and Bioengineering (H.P.). The content of the information within this document does not necessarily reflect the position or the policy of the Government. Furthermore, this project has been funded in part by the National Institutes of Health, through contract number R01 AI132413-01. Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-04390-7",

language = "English (US)",

volume = "9",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus

AU - Kim, Byungji

AU - Pang, Hong Bo

AU - Kang, Jinyoung

AU - Park, Ji Ho

AU - Ruoslahti, Erkki

AU - Sailor, Michael J.

N1 - Funding Information: This work supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017, in part by grant CA152327 from the National Cancer Institute of the U.S. National Institutes of Health (E.R.), and by grant EB022652 from National Institute of Biomedical Imaging and Bioengineering (H.P.). The content of the information within this document does not necessarily reflect the position or the policy of the Government. Furthermore, this project has been funded in part by the National Institutes of Health, through contract number R01 AI132413-01 Funding Information: This work supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement HR0011-13-2-0017, in part by grant CA152327 from the National Cancer Institute of the U.S. National Institutes of Health (E.R.), and by grant EB022652 from National Institute of Biomedical Imaging and Bioengineering (H.P.). The content of the information within this document does not necessarily reflect the position or the policy of the Government. Furthermore, this project has been funded in part by the National Institutes of Health, through contract number R01 AI132413-01. Publisher Copyright: © 2018 The Author(s).

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The incidence of adverse effects and pathogen resistance encountered with small molecule antibiotics is increasing. As such, there is mounting focus on immunogene therapy to augment the immune system's response to infection and accelerate healing. A major obstacle to in vivo gene delivery is that the primary uptake pathway, cellular endocytosis, results in extracellular excretion and lysosomal degradation of genetic material. Here we show a nanosystem that bypasses endocytosis and achieves potent gene knockdown efficacy. Porous silicon nanoparticles containing an outer sheath of homing peptides and fusogenic liposome selectively target macrophages and directly introduce an oligonucleotide payload into the cytosol. Highly effective knockdown of the proinflammatory macrophage marker IRF5 enhances the clearance capability of macrophages and improves survival in a mouse model of Staphyloccocus aureus pneumonia.

AB - The incidence of adverse effects and pathogen resistance encountered with small molecule antibiotics is increasing. As such, there is mounting focus on immunogene therapy to augment the immune system's response to infection and accelerate healing. A major obstacle to in vivo gene delivery is that the primary uptake pathway, cellular endocytosis, results in extracellular excretion and lysosomal degradation of genetic material. Here we show a nanosystem that bypasses endocytosis and achieves potent gene knockdown efficacy. Porous silicon nanoparticles containing an outer sheath of homing peptides and fusogenic liposome selectively target macrophages and directly introduce an oligonucleotide payload into the cytosol. Highly effective knockdown of the proinflammatory macrophage marker IRF5 enhances the clearance capability of macrophages and improves survival in a mouse model of Staphyloccocus aureus pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=85047247683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047247683&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04390-7

DO - 10.1038/s41467-018-04390-7

M3 - Article

C2 - 29773788

AN - SCOPUS:85047247683

SN - 2041-1723

VL - 9

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 1969

ER -

Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this